Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Conditions
Interventions
E/C/F/TDF
ATV
+7 more
Locations
99
United States
University of Southern California AIDS Clinical Trials Group
Los Angeles, California, United States
University of California, Davis Medical Center
Sacramento, California, United States
Whitman-Walker Health
Washington D.C., District of Columbia, United States
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, United States
Midway Immunology and Research Center
Ft. Pierce, Florida, United States
University of Miami
Miami, Florida, United States
Start Date
October 24, 2012
Primary Completion Date
February 9, 2015
Completion Date
September 6, 2018
Last Updated
September 20, 2019
NCT06627764
NCT04142047
NCT06694805
NCT07428330
NCT05398185
NCT07225530
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions